There are IPO debuts, and then there are Anthem Biosciences moments—the kind that makes you stop, watch, and feel the rush of the stock market in action. On July 21, 2025, Anthem stormed the Indian stock exchanges with the kind of confidence and investor euphoria we haven’t seen in months. The stock opened at ₹723.10, a whopping 27% above its IPO price of ₹570, and didn’t stop there. Within hours, it touched ₹746.70 before finally settling at ₹731.65. That’s a first-day gain of over 28%, making it one of the most talked-about listings this year.
For someone closely following the IPO, the energy was palpable. Social media was buzzing. WhatsApp groups were full of messages like “Hold or sell?” and “Is this the next Divi’s Labs?” And honestly, who could blame them?
The IPO Frenzy: A Stampede of Buyers
It’s not every day that an IPO gets oversubscribed 28 times, and that too with 40x demand from big institutional players. Retail investors, who usually tread cautiously, went 9 times overboard. Even high-net-worth individuals and family offices came in strong, pushing their segment 22 times over the available shares.
This kind of response doesn’t happen without solid trust in the company’s future. And it tells us one thing clearly: investors believe in Anthem.
Why Is Anthem Biosciences So Special?
Now, let’s step back and ask—what’s making everyone so excited?
Well, Anthem isn’t just another pharmaceutical company. It has built a strong reputation as a full-service partner for global pharma and biotech giants. Think of them as the behind-the-scenes experts helping others develop, test, and manufacture complex drugs.
Here’s what stands out:
-
They don’t rely on just one client or one product. Their customer base is wide and global. That brings in steady revenue, month after month.
-
Their margins are high, and as they scale, profits rise faster than costs—a dream for any business.
-
They’re future-ready. With the growing demand for outsourced drug development (CRDMO), Anthem is perfectly positioned to ride that growth wave.
Honestly, when you look at this business model, it just makes sense why institutions threw money at it. It’s scalable, predictable, and deeply connected to the global healthcare ecosystem.
But What About Valuation?
Here comes the reality check.
While the business is rock solid, the valuation is steep—some might say too steep. Anthem is currently trading at a P/E of around 81–91x and a price-to-book of 24x. That’s way higher than many of its listed peers. And as we all know, a great company doesn’t always mean a great investment at any price.
This is why some market experts are advising short-term traders to be cautious. The debut was strong, yes, but a pullback or price correction could happen, especially if profit-booking kicks in.
What Are Experts Saying? Hold or Sell?
Right now, there’s a clear split in opinions:
-
Short-term traders are being advised to book partial profits, especially if the stock stays near the ₹730–750 range.
-
Long-term investors are being told to stay calm and hold. If Anthem keeps showing strong earnings, a ₹900–₹1000 target in the next 12–18 months isn’t unrealistic.
-
New buyers? Most experts suggest waiting for a correction—somewhere between ₹650 and ₹680 might be a safer entry zone.
The logic is simple: you don’t chase a stock after it’s already up 28%—not unless you’ve got a very strong conviction or a long-term view.
If you’re someone who’s looking for long-term wealth creation and can stomach a few ups and downs, Anthem might be worth adding gradually—on dips, not at peaks. Maybe start with small, staggered purchases if the price cools off.
But if you’re just looking for quick gains, the smart move might be to lock in profits now and re-enter later. The stock is a bit hot right now, and as always, markets don’t stay euphoric forever.
The Road Ahead: Promising, But Stay Alert
The IPO debut of Anthem Biosciences is more than just a one-day event—it reflects the strong future of India’s biotech and pharmaceutical sector. The country’s pharma exports are rising, global outsourcing is gaining pace, and Anthem has the right mix of capabilities and scale to ride this wave.
But remember, even great businesses face challenges. The next few quarters will be crucial. We’ll need to watch how Anthem delivers on earnings, wins new contracts, and manages costs.
Final Thoughts
Anthem Biosciences has made a stellar entrance on Dalal Street, no doubt. It checks many boxes: strong demand, global relevance, high margins, and a future-proof model. But it also comes with a premium price tag, which means investors need to tread carefully.
If you’re already in, stay informed and maybe trim a bit if the price rises too fast. If you’re still watching from the sidelines, don’t rush—opportunities often knock twice in the market.
As always, do your own homework, think long-term, and speak with a financial advisor before making any big investment decisions.
